Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

Molecular Imaging and Biology

Volumn 17, Issue 4, 2015, Pages 575-584

  Dietlein, Markus ^a   Kobe, Carsten ^a   Kuhnert, Georg ^a   Stockter, Simone ^a   Fischer, Thomas ^a   Schomäcker, Klaus ^a   Schmidt, Matthias ^a   Dietlein, Felix ^a   Zlatopolskiy, Boris D ^a   Krapf, Philipp ^a   Richarz, Raphael ^a   Neubauer, Stephan ^b   Drzezga, Alexander ^a   Neumaier, Bernd ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Klinik am Ring   (Germany)

Author keywords

F 18; Ga 68; Positron emission tomography (PET); Prostate cancer; Prostate specific membrane antigen (PSMA)

Indexed keywords

2 (3 [1 CARBOXY 5 [(6 FLUOROPYRIDINE 3 CARBONYL)AMINO]PENTYL]UREIDO)PENTANEDIOIC ACID F 18; HBED CC GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG; 2-(3-(1-CARBOXY-5-((6-FLUOROPYRIDINE-3-CARBONYL)AMINO)PENTYL)UREIDO)PENTANEDIOIC ACID; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); LYSINE; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; UREA;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMAGE QUALITY; KIDNEY; LIVER; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SPLEEN; VERY ELDERLY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RECURRENT DISEASE;

AGED; AGED, 80 AND OVER; EDETIC ACID; HUMANS; LIVER; LYSINE; MALE; MIDDLE AGED; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECURRENCE; UREA;

EID: 84937521365     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0866-0     Document Type: Article

References (22)

1. Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
2. 68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
3. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20
4. 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41(5):887–897
5. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209
6. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-014-2978-1
7. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292
8. Chang SS, Reuter VE, Heston WDW et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198
9. Haffner MC, Kronberger IE, Ross JS et al (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancer. Human Pathol 40:1754–1761
10. 18F]DCFPyl, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17(24):7645–7653
11. Eder M, Schäfer M, Bauder-Wüst U et al (2012) (68) Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697
12. 68Ga-PET imaging of prostate cancer. EJNMMI Res 2:23
13. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 7:779–796
14. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. doi:10.1007/s11307-015-0850-8
15. 68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 42:210–214
16. Mannweiler S, Amersdorfer P, Trajanoski S et al (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167–172
17. Bostwick DG, Pacelli A, Blute M et al (1998) Prostate specific membrane antigen expression in prostate intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261
18. 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38:55–63
19. Graute V, Jansen N, Übleis C et al (2012) Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 39:271–281
20. Rigatti P, Suardi N, Briganti A et al (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline PET/CT. Eur Urol 60:935–943
21. 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 99:193–200
22. 18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiation. Oncology 6:44